Health Economics›Head and neck cancer›Recurrent or metastatic disease first-line therapy

Recurrent or metastatic disease first-line therapy

Head and neck cancer · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	11.6 mo	—	—	1
Cisplatin and Cetuximab Variant #01	—	R 96 965	28d	—	—	—	—	—
Carboplatin, Fluorouracil, Pembrolizumab Variant #01	—	R 83 563	21d	—	13.0 mo	—	—	1
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 82 937	21d	—	13.0 mo	—	—	1
Carboplatin, Fluorouracil, Cetuximab Variant #01	—	R 75 607	21d	—	10.7 mo	—	—	3
Cisplatin and Fluorouracil (CF) and Cetuximab Variant #01	—	R 74 819	21d	5.5 mo	10.9 mo	8	R 598 553 PFS proxy	5
Cisplatin and Fluorouracil (CF) and Panitumumab Variant #01	—	R 38 931	21d	—	11.1 mo	—	—	1
Celecoxib, Erlotinib, Methotrexate, Nivolumab Variant #01 Partial	—	R 10 531	21d	—	—	—	—	1
Celecoxib, Erlotinib, Methotrexate Variant #01	—	R 3 510	7d	—	—	—	—	1
Carboplatin and Docetaxel (DCb) Variant #01	—	R 3 300	21d	~4.7 mo	~22.3 mo	~7	~R 23 101 PFS proxy · indirect	4
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	11.3 mo	9.0 mo	17	R 32 301 PFS proxy	8
Carboplatin and Fluorouracil Variant #01	—	R 1 781	21d	—	7.4 mo	—	—	1
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	~10.0 mo	—	—	3
CABO Variant #01	—	R 743	21d	—	—	—	—	—
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	—	8.1 mo	—	—	—
Cisplatin monotherapy Variant #16	—	R 650	28d	2.7 mo	6.2 mo	3	R 1 950 PFS proxy	3
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	—	—	—	—	1
Celecoxib and Methotrexate Variant #01	—	R 34	7d	—	7.5 mo	—	—	1
Methotrexate monotherapy Partial	—	—	—	—	6.7 mo	—	—	2

19 of 19 regimens shown